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Abstract: Primary coenzyme Q10 (CoQ10) deficiency is unique among mitochondrial respiratory 
chain disorders in that it is potentially treatable if high-dose CoQ10 supplements are given in the 
early stages of the disease. While supplements improve peripheral abnormalities, neurological 
symptoms are only partially or temporarily ameliorated. The reasons for this refractory response to 
CoQ10 supplementation are unclear, however, a contributory factor may be the poor transfer of 
CoQ10 across the blood–brain barrier (BBB). The aim of this study was to investigate mechanisms of 
CoQ10 transport across the BBB, using normal and pathophysiological (CoQ10 deficient) cell culture 
models. The study identifies lipoprotein-associated CoQ10 transcytosis in both directions across the 
in vitro BBB. Uptake via SR-B1 (Scavenger Receptor) and RAGE (Receptor for Advanced Glycation 
Endproducts), is matched by efflux via LDLR (Low Density Lipoprotein Receptor) transporters, 
resulting in no “net” transport across the BBB. In the CoQ10 deficient model, BBB tight junctions 
were disrupted and CoQ10 “net” transport to the brain side increased. The addition of anti-oxidants 
did not improve CoQ10 uptake to the brain side. This study is the first to generate in vitro BBB 
endothelial cell models of CoQ10 deficiency, and the first to identify lipoprotein-associated uptake 
and efflux mechanisms regulating CoQ10 distribution across the BBB. The results imply that the 
uptake of exogenous CoQ10 into the brain might be improved by the administration of LDLR 
inhibitors, or by interventions to stimulate luminal activity of SR-B1 transporters. 
Keywords: coenzyme Q10; coenzyme Q10 deficiency; blood–brain barrier; bEND.3; PBEC; 
mitochondrial dysfunction; lipoprotein; LDLR; RAGE; SR-B1; LC-MS/MS 
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1. Introduction 
Coenzyme Q10 (CoQ10) plays an important role in oxidative phosphorylation where it acts as an 
electron carrier in the mitochondrial respiratory chain (MRC). Its major role is in accepting electrons 
derived from complex I and II (NADH ubiquinone reductase; succinate ubiquinone reductase) and 
transporting them to complex III (ubiquinol cytochrome c reductase) [1]. In addition to this, CoQ10 
also serves as an antioxidant and an essential component in the functional superassembly of the so-
called “respirasome” [2], which improves efficiency and prevents electron leakage and production of 
reactive oxygen species (ROS). 
CoQ10 deficiencies are defined by decreased cellular CoQ10 content, and pathogenesis involves 
both reduced ATP production and increased ROS production [3]. Primary CoQ10 deficiencies stem 
from mutations in genes required for CoQ10 biosynthesis (nine genes have been identified [3]) while 
secondary deficiencies are associated with diseases that do not result from a genetic defect in the 
CoQ10 biosynthetic pathway and include disorders such as primary MRC deficiencies and organic 
acidemias [4]. A failure in CoQ10 biosynthesis could therefore contribute to disease pathophysiology 
by causing a failure in energy metabolism and/or increased oxidative stress. 
The clinical presentation of CoQ10 deficiency is heterogeneous, however, there are five distinct 
clinical phenotypes: encephalomyopathy; severe infantile multisystemic disease; nephropathy; 
cerebellar ataxia and isolated myopathy [5]. Since the first description of human CoQ10 deficiency in 
1989, over 150 cases have been reported, with cerebellar ataxia being the most common clinical 
presentation of this disorder [5]. Many patients respond well to oral supplementation of high dose 
CoQ10 which can stop the progression of the encephalopathy [6,7]. However, in other patients with 
predominantly central nervous system (CNS) manifestations including ataxia, seizures or dystonia 
characterised by recessive ADCK3 mutations, which encodes for a protein kinase that is involved in 
CoQ10 biosynthesis and its regulation [8], there is often no or limited clinical benefit of CoQ10 
supplementation [9]. Indeed, only 49% of patients with the cerebellar ataxic phenotype have been 
reported to demonstrate improvement/stabilisation in their ataxic symptoms following CoQ10 
supplementation [5]. 
The reasons for the refractory nature of these neurological symptoms to CoQ10 supplementation 
remain unknown. However, a major contributory factor may be the poor transfer of CoQ10 across the 
blood–brain barrier (BBB) into CNS, resulting in insufficient CoQ10 availability for the deficient 
neurons. Relatively little is known about how plasma CoQ10 interacts with the BBB or whether CoQ10 
deficiency of the BBB itself may affect transport into the central nervous system. Plasma CoQ10 is in 
the form of reduced CoQ10H2, or ubiquinol, and carried by lipoproteins including HDL, LDL, vLDL 
[10], following absorption in the small intestine and processing by the liver [11]. Lipoproteins serve 
to solubilise lipophilic compounds such as CoQ10, and transport them through the aqueous 
circulatory system. Specific apoproteins present on the surface of the macromolecule facilitate their 
targeting to appropriate tissues by receptor-mediated endocytic processes. 
At the BBB, there are multiple membrane transporters for uptake and efflux that interact with 
lipoproteins [12], but these generally act together to limit systemic lipoprotein transfer into the brain. 
An exception is HDL which traverses the BBB by caveolin-mediated transcytosis after interaction 
with the SR-B1 scavenger receptor on the apical (blood side) of the BBB [13]. Under normal 
circumstances, systemic lipoprotein and cholesterol are not required by the brain because there is 
sufficient de novo synthesis, mainly by astrocytes [14]. 
In this study, we assessed the permeability of an in vitro BBB model to CoQ10 and the effect of 
induced CoQ10 deficiency on transport. Using pharmacological inhibitors of BBB lipoprotein 
transporters, we also investigated their effect on CoQ10 transport, specifically, BLT-1 inhibitor of SR-
B1 (Scavenger Receptor) mediated HDL uptake [15], the receptor-associated protein (RAP) inhibitor 
of the Low-Density Lipoprotein Receptor (LDLR) superfamily [16], including LRP-1, vLDLR, 
apoER2, and LDLR; and FPS-ZM1 inhibitor of the receptor for advanced glycation end products 
(RAGE) which opposes LRP-1 as part of apolipoprotein E-amyloid beta homeostasis [17]. In addition, 
the efflux transporter P-glycoprotein (ABCB1) was studied since it is reported to reduce CoQ10 
transport across the Caco-2 intestinal epithelial-barrier model [18]. 
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2. Experimental Section 
2.1. Materials 
Unless otherwise stated all materials were supplied by Sigma-Aldrich Company Ltd., UK. 
2.2. CoQ10 Analysis by Liquid Chromatography-Tandem Mass Spectrometry 
A novel CoQ10 liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was 
established. The method is a modified version of that described by Itkonen et al. [19], in combination 
with a variation of the sample preparation outlined by Duncan et al. [20]. The lower limit of 
quantitation for this method is 0.25 nmol/L, with a limit of detection at 0.125 nmol/L, and linearity up 
to 500 nmol/L. The run-time (inject-to-inject) is 7 min per sample. 
Samples were prepared by the addition of stable isotope-labelled internal standard (CoQ10–[2H9]; 
IsoSciences LLC, Ambler, PA, USA) to each sample (200 μL), with a subsequent freeze–thaw process 
(× 3) to perturb cellular membranes. Extraction buffer was then added (800 μL/sample; 5:2 (v/v) 
hexane/ethanol) and the samples vigorously mixed on a vortex for 1 min, centrifuged at 18,625× g for 
3 min, and the top layer of hexane collected. The hexane extract was evaporated to dryness using a 
centrifugal evaporator. Prior to analysis, calibrators and samples were re-constituted in LC-MS/MS 
“running solvent A” (50 μL; 41:9 (v/v) methanol/1-propanol with 500 μmol/L ammonium acetate), 
vigorously mixed, and transferred into a suitable vial. CoQ10 calibration curves (0, 0.25, 0.5, 1.0, 2.5, 
5.0, 25, 50, 500 nmol/L CoQ10 in ethanol) were established through serial dilutions of a 1 mM stock 
solution, as confirmed by the spectrophotometric method first described by Crane et al. [21]. 
Chromatography was performed on an Agilent Technologies 1200 Series LC system (Agilent 
Technologies, USA) using an ACE® UltraCore™ 2.5 μm SuperC18™ 30 × 2.1 mm reversed-phase 
column (Advanced Chromatography Technologies Ltd., UK) kept at 25oC with a gradient of running 
solvent A (41:9 (v/v) methanol/1-propanol with 500 μmol/L ammonium acetate) and running solvent 
B (1:1 (v/v) methanol/1-propanol with 500 μmol/L ammonium acetate). The gradient elution profile 
was maintained at 100% A (0–0.2 min), ramped to 100% B (0.21–1 min), maintained at 100% B (1–3.5 
min), and ramped back to 100% A (3.51–3.6 min). Total run time was 6.5 min with a flow rate of 220 
μL/min and injection volume of 10 μL. 
Mass spectrometry was performed on an AB Sciex™ QTRAP® 6500 (ESI)-MS/MS (AB Sciex™, 
UK), operated in positive ion mode with the ion source spray voltage at 5500 V, declustering potential 
at 50 V, temperature at 115 °C, and collision energy at 27 V. The curtain gas was 48 L/min, gas 1 
(nebuliser gas) 55 L/min, gas 2 (heater gas) 21 L/min, and collision gas on “medium” setting. The 
mass spectrometer was programmed to monitor the transitions of m/z 880.7   197.1 (dwell time 
200 ms) corresponding to the ammonium adduct of CoQ10, and m/z 889.7   206.1 (dwell time 200 
ms) corresponding to the ammonium adduct of CoQ10–[2H9]. 
Final CoQ10 concentrations (nmol/L) were calculated as a ratio of CoQ10/CoQ10–[2H9] peak areas, 
and quantified against the corresponding calibration curve, with appropriate correction for dilution. 
For intracellular determination of CoQ10 the concentration was divided by total protein (mg/mL) and 
expressed as pmol/mg (nmol/g) of protein. 
2.3. Blood–Brain Barrier Cell Culture 
Two BBB cell culture models were used in this study. The bEND.3 cell line is a widely 
characterised, consistent, and easy to use in vitro BBB model, which was used as the main tool to 
interrogate lipoprotein-CoQ10 transport. Key findings using bEND.3 cells were then replicated using 
primary porcine brain endothelial cells for validation. 
Primary porcine brain endothelial cells (PBEC) were isolated and cultured as previously 
published [22]. Briefly, cells were seeded at 10 × 104 cells/cm2 on collagen and fibronectin-coated 
polycarbonate Transwell filters (Corning 0.4 μm pore size) in 12-well plates, and grown in low 
glucose DMEM (Sigma D5546) supplemented with bovine plasma-derived serum (10% v/v; BPDS, 
First Link UK), glutamine (2 mM), heparin (125 μg/mL), penicillin (100 U/mL) and streptomycin (100 
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μg/mL), at 37 °C in a 5% CO2 incubator. PBECs were grown in non-contact co-culture above primary 
rat astrocytes until confluent, then supplemented with hydrocortisone (550 nM), 8-4-
chlorophenylthio-cAMP (250 μM) and RO-20-1724 (17.5 μM) in serum-free medium for a further 3 
days. Before assays of CoQ10 transport, PBECs were separated from astrocytes by moving transwell 
filters to fresh culture plates. PBEC monolayer tightness was assessed by transendothelial electrical 
resistance (TEER, STX100C Electrode) and FITC-dextran 40 (FITC-40) paracellular permeability 
(Papp), as previously described by Patabendige et al. [23]. The TEER averaged 946 ± 94 Ω.cm2 (after 
subtraction of blank 160 Ω.cm2) and FITC-40 Papp averaged 1.3 ± 0.1 × 10−6 cm.sec−1 (n = 12). High 
TEER and low paracellular permeability demonstrate a tight BBB monolayer. 
The mouse BBB cell line, bEnd.3 (ATCC CRL-2299) was used for pharmacological screening of 
potential transport system inhibitors. Cells, between passage 24–28, were seeded at 2.5 × 104 cells/cm2 
onto collagen-coated Transwell filters (Corning 0.4 μm pore size) in 12 well plates, and grown in 
DMEM (ATCC, 30-2002) with foetal bovine serum (10% v/v), penicillin (100 U/mL) and streptomycin 
(100 μg/mL) until confluent. The TEER and FITC-40 Papp averaged 40.8 ± 3.2 Ω.cm2 (after subtraction 
of blank 160 Ω.cm2) and 3.3 ± 0.4 × 10−6 cm.sec−1 (n = 12) respectively. The tight-junction integrity of 
bEnd.3 monolayers is lower when compared to PBEC, but suitable for assessing permeability of 
macro-molecules across a monolayer (e.g., lipoproteins) while less suitable for small molecules (~400 
g/mol) due to paracellular leak. 
2.4. Coenzyme Q10 Transport Assays 
Cell medium was replaced by an assay buffer of HBSS (without phenol red), bovine serum 
albumin (BSA; 0.5% w/v), HEPES (25 mM) titrated to pH 7.4 and FITC-40 (1 mg/mL). Unless stated, 
CoQ10 was pre-treated by incubation in serum at a concentration of 20 μM for 45 min at 37 °C, and 
added to assay buffer on either the Apical (blood facing) or Basal (brain facing) side of the cells on 
Transwell filters. The final concentration of CoQ10 used in the assays was 10 μM in serum (50% v/v). 
Cells were then incubated for 60 min on an orbital shaker (100 rpm) at 37 °C. Samples of the Apical 
(A) and Basal (B) media were then taken for analysis to calculate A to B (blood-to-brain) or B to A 
(brain-to-blood) Papp in cm/s, as previously described by Patabendige et al. [23]. CoQ10 concentrations 
were determined using the LC-MS/MS method described above (Section 2.2). FITC-40 was measured 
fluorometrically (excitation 485/20 nm, emission 528/20 nm, sensitivity 50) on a Synergy™ HT plate 
reader with KC4™ data analysis software (BioTek Instruments Ltd., Cheadle, UK). 
Inhibitors of transport were added to both Apical and Basal sides of the cells for 2 h prior to 
assay. Antioxidants were pre-incubated with CoQ10 in serum for 45 min prior to assay, and were 
present in the assay buffer. Compounds used were; SR-B1 inhibitor, blocker of lipid transport-1 (BLT-
1; 10 μmol/L) [15] LDLR superfamily inhibitor, RAP (0.5 μmol/L) [24]; RAGE inhibitor, FPS-ZM1 (1 
μmol/L) [25]; P-glycoprotein inhibitor, verapamil 0.1 mmol/L [26]; α-tocopherol (vitamin E; 50 
μmol/L) [27]; and Trolox (50 μmol/L). 
2.5. Cellular CoQ10 Depletion and Mitochondrial Respiratory Chain Enzyme Activity 
As previously described, para-aminobenzoic acid (pABA) was used as a pharmacological reagent 
to induce CoQ10 deficiency [3,28,29]. The mechanism of action is via competitive inhibition of 
polyprenyl-4-hydroxybenzoate transferase (Coq2p), a key enzyme in the later stages of the CoQ10 
biosynthetic pathway. Following the method of Duberley et al. [29], 1 mmol/L pABA was added to 
culture medium for 5 days prior to assay. 
Activities of the mitochondrial respiratory chain enzymes; complex I, complex II-III and complex 
IV together with the mitochondrial marker enzyme, and citrate synthase (EC 2.3.3.1) were determined 
spectrophotometrically on a Uvikon XL spectrophotometer with LabPower software (Northstar 
Scientific Ltd., UK) according to the method previously described by Hargreaves et al. [30]. Results 
were expressed as a ratio to citrate synthase activity, a validated biomarker of mitochondrial content, 
and were normalised against mg protein. Protein quantification was determined according to the 
Lowry method [31] using BSA as a standard. 
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2.6. Cell Viability Assay 
Cell viability was determined using the MTT assay described by Mosmann [32]. Cells were 
passaged onto 96-well plates, grown to confluence and washed with HBSS prior to the addition of 3-
[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT; 1 mg/mL) in DMEM (without 
phenol red). Cells were then incubated for 4 h at 37 °C, 5% CO2, after which the medium was 
removed, and the remaining formazan crystals dissolved in propan-2-ol (100 μL/well). The resulting 
purple solution was spectrophotometrically measured at 540 nm using a Multiskan Ascent plate 
reader with Ascent software (MTX LabSystems, USA). 
2.7. CoQ10 Partition in Serum Lipoprotein Fractions 
Bovine plasma-derived serum (BPDS) was either untreated or supplemented with 10 μM CoQ10 
for 45 min at 37 °C. Serum lipoproteins were then fractionated according to the method of Ononogbu 
et al. [33] and the CoQ10 content measured in each fraction by LC-MS/MS. This lipoprotein fraction 
method is comprised of two parallel precipitation-centrifugation extractions, yielding a separation of 
the major classes of lipoprotein as supernatants containing “LDL + HDL” and “HDL”. The 
concentration of CoQ10 in the “VLDL” fraction was calculated by subtraction. 
2.8. Confocal Microscopy 
Cells for confocal microscopy were fixed in paraformaldehyde (4% w/v in PBS) for 45 min, 
washed with HBSS and stored in glycerol (70% v/v in PBS) until use. Cells were permeabilised with 
Triton-x 100 (0.1% v/v in PBS), incubated with anti-Claudin 5 Monoclonal Antibody (4C3C2) Alexa 
Fluor 488 (1 in 80 dilution in DAKO, overnight, 4 °C, Thermofisher) to visualise tight junctions. 
Samples were then mounted in Vectashield containing DAPI for nuclei staining. The Nikon A1 
inverted confocal microscope was used with spectral detector and Eclipse Ti-E microscope at x40 
magnification to generate digital images, analysed using Fiji (ImageJ). 
2.9. Statistical Analysis 
All results are expressed as mean ± standard error of the mean (SEM). Individual comparisons 
of means were made using the two-sample Student’s t-test and were carried out using Microsoft® 
Excel with AnalystSoft® StatPlus software. To reduce the incidence of type 1 error that is associated 
with performing multiple two-sample t-tests, one-way ANOVA was used for comparison of groups 
> 2, with Bonferroni post-hoc analysis. In all cases, p < 0.05 was considered significant. 
3. Results 
3.1. LC-MS/MS CoQ10 Method Validation 
The lower limit of detection (LLOD) for the LC-MS/MS method was 0.125 nmol/L and defined 
as a signal-to-noise ratio of 3 (n = 6). Linearity and lower limit of quantitation (LLOQ) were 
determined across a 10-point serial dilution (0–500 nmol/L) performed on six separate days with six 
separate preparations, and defined as the lowest concentration and range, respectively, that could be 
measured with an inaccuracy (percentage relative error) and imprecision (CV%) < 20% (n = 6) [34,35]. 
For this method, the LLOQ was found to be 0.25 nmol/L with linearity up to 500 nmol/L. This 
performance surpasses the current HPLC-UV [20] technique which is commonly used for clinical 
diagnosis (Table 1). However, we did not compare this LC-MS/MS method with HPLC-
electrochemical detection which is an analytical technique that can also be used for the clinical 
assessment of CoQ10 and has the ability to determine both the CoQ10 and ubiquinol species in tissues 
[36]. 
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Table 1. Comparison of performance parameters for the liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) and HPLC-UV [20] CoQ10 methods. 
 LC-MS/MS HPLC-UV 
LLOQ (nmol/L) 0.25 10 
LLOD (nmol/L) 0.125 6 
Linearity (nmol/L) 500 200 
Run Time (minutes) 7 25 
The precision of the LC-MS/MS method was assessed by evaluating the intra- and inter-assay 
coefficient of variation (CV), with acceptable CV values being defined as < 15% [34,35,37]. The intra-
assay precision was determined across replicates of three parallel samples of internal QC (IQC) 
material (n = 8; baseline, low spike, high spike). Inter-batch precision was calculated as the CV of 
average values for parallel samples of QC material over seven separate days (n = 2; baseline, low 
spike, “plasma” QC). The results (Table 2) indicate that the LC-MS/MS method has good 
reproducibility across the range. 
Table 2. Summary of the validation metrics for the LC-MS/MS CoQ10 method. 
 
Intra-assay imprecision 
(CV%) 
Inter-assay imprecision 
(CV%) 
Recovery 
(Ave.%) 
Baseline  3.6 7.2 − 
Low Spike (10 nmol/L) 5.6 6.4 84 
High Spike (100 nmol/L) 5.9 − 103 
EQC Plasma − 6.7 − 
Accuracy was investigated by examining the average recovery of known quantities of CoQ10 in 
replicates of spiked samples (n = 8; low spike (+ 10 nmol/L), high spike (+ 100 nmol/L)). A negligible 
inaccuracy (3%) was observed for the high spike at 100 nmol/L. The relatively low, but consistent, 
recovery (84%) for the low spiked CoQ10 sample at 10 nmol/L could be due to adsorption losses 
during sample preparation, but overall the method exhibits an acceptable degree of accuracy across 
the range (Table 2). 
Carry-over between successive samples was assessed by analysing a blank sample immediately 
after the highest calibrator standard (ULOQ; 500 nmol/L) (n = 7). No quantifiable carryover was 
observed for the LC-MS/MS method. 
These results suggest that LC-MS/MS could be a viable alternative to current clinical techniques, 
namely HPLC-UV, and offers improved performance which could prove advantageous for the timely 
diagnosis of CoQ10 deficiencies in humans. 
3.2. Effect of Serum Pre-Incubation on CoQ10 Transport Across In Vitro BBB 
To date, the highest achievable CoQ10 plasma concentration observed after oral-supplementation 
in vivo is 10.7 μmol/L [38,39], and treatment with 10 μmol/L CoQ10 restores MRC function in CoQ10 
deficient human neuroblastoma cells [40]. Therefore, 10 μmol/L CoQ10 was selected as the clinically 
relevant concentration for use in this study. 
The time course for CoQ10 transport across the primary PBEC model of the BBB was initially 
assessed for Apical to Basal transport (A to B, blood-to-brain side). Transport to the Basal side, 
expressed as a percentage of CoQ10 in the Apical compartment, was undetectable at 30 min (Figure 
1a). After 2 h, the percentage in the Basal compartment rose to 0.51 ± 0.15%, but was still lower than 
the paracellular marker FITC-40 which was 1.03 ± 0.17% (n = 4). Based on data that CoQ10 is carried 
by lipoproteins in blood, CoQ10 was pre-incubated in serum (BPDS) for 45 min for adsorption of 
lipophilic CoQ10 to the range of endogenous lipoproteins, and the assay repeated. Total CoQ10 in the 
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Apical compartment was unchanged (10.2 ± 1.1 μM and 9.0 ± 0.7 μM CoQ10 respectively), but 
transport across the PBEC monolayer increased 4-fold (Figure 1a) suggesting that CoQ10 may be 
primarily transported as part of a lipoprotein complex. 
Since lipoprotein entry to the brain is tightly regulated by both uptake and efflux transporters, 
CoQ10 transport in both directions was compared (Figure 1b schematic), A to B (blood-to-brain) and 
B to A (brain-to-blood). Pre-incubation of CoQ10 in serum enhanced transport in both directions and 
was seen for primary PBEC monolayers (Figure 1c) and the mouse BBB cell line, bEnd.3 (Figure 1d), 
without a change in paracellular permeability (Figure 1e). Interestingly, transport in the A to B 
direction was matched by transport in the B to A direction. This means that although transport across 
the BBB is possible, there may be no “net” accumulation of CoQ10 in the brain because of opposing 
transport systems. 
 
Figure 1. Effect of pre-incubating CoQ10 in serum, on transport across the blood–brain barrier (BBB) 
in vitro models. (a) CoQ10 transport across porcine brain endothelial cells (PBEC) monolayer is 
increased by pre-incubation of CoQ10 in serum. CoQ10 was either pre-incubated for 45 min in serum, 
or added directly to apical assay buffer (no serum), and appearance in the basal buffer measured after 
30, 60 or 120 min; n = 4–7. (b) Schematic of transport assays using BBB cells grown on Transwell filters. 
CoQ10 and FITC-40 can be added to the apical compartment to measure transport from blood-to-brain, 
(apical to basal), or to the basal compartment to measure brain-to-blood transport (basal to apical). 
CoQ10 Papp across PBEC (c) and bEnd.3 (d) monolayers after 60 min. Transport in both directions, 
blood-to-brain side (A to B) and brain-to-blood side (B to A) was increased after pre-incubation of 
CoQ10 in serum; n = 4–10. (e) FITC-40 Papp across b.End3 monolayer over 60 min. Pre-incubation of 
FITC-40 in serum did not change transport in either direction; n = 6–12. Values are mean ± SEM; * p < 
0.05, ** p < 0.01. 
3.3. CoQ10 Distribution in Serum Lipoprotein Fractions 
The distribution of CoQ10 in major lipoprotein fractions was assayed in cell culture serum before 
(untreated) and after 45 min pre-incubation with CoQ10. The serum’s endogenous CoQ10 content was 
147.5 ± 0.5 nM and the majority was incorporated in the LDL fraction (77.7%, Table 3). In serum 
supplemented with 10 μM CoQ10, content increased in all fractions; HDL, LDL and vLDL. The LDL 
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fraction still showed the greatest association, but CoQ10 distribution in the vLDL fraction increased 
greatly from <1% to 29%. More than 92% of supplemented CoQ10 was recovered in the vLDL/LDL 
fractions, confirming that lipoproteins are the main bio-carrier of CoQ10 and suggesting that the 
transport of CoQ10 at the BBB will be predominately mediated by lipoprotein interactions. 
Table 3. Distribution of CoQ10 in the major lipoprotein fractions. 
Lipoprotein Fraction Untreated Serum CoQ10 nmol/L Supplemented serum CoQ10 nmol/L 
HDL 32.7 ± 1.8 (21.7%) 762 ± 8.1 (7.2%) 
LDL 117.0 ± 1.2 (77.7%) 6718 ± 103.5 (63.8%) 
vLDL 0.9 ± 0.01 (0.6%) 3060 ± 138.8 (29.0%) 
Bovine plasma-derived serum was either untreated, or supplemented with 10 μmol/L CoQ10, and 
incubated for 45 min. Lipoprotein fractions were separated and CoQ10 content measured by LC-
MS/MS, n = 3. CoQ10 content is given in nmol/L and the% in each fraction in parentheses. HDL, high-
density lipoprotein; LDL, low-density lipoprotein; VLDL, very-low-density lipoprotein. 
3.4. CoQ10 BBB Transport: SR-B1, LDLR, and RAGE Inhibitors 
Based on known transport systems at the BBB for general classes of lipoproteins, relevant 
pharmacological inhibitors were screened for their effect on CoQ10 transport across bEnd.3 cells. The 
inhibitors were: BLT-1, which irreversibly inhibits the HDL receptor SR-B1, a receptor that also 
mediates vLDL uptake in hepatocytes [41]; RAP, which is widely used to inhibit the LRP-1 
transporter for LDL, but also inhibits other members of the LDLR family of transporters; the RAGE 
inhibitor FPS-ZM1, because of the well-documented action of RAGE to oppose LRP-1 transport 
involving amyloid-beta and apoE; and finally, the p-glycoprotein inhibitor, verapamil was chosen to 
target this ABC efflux transporter, thought to mediate CoQ10 efflux in other cell lines. 
Inhibitors of both SR-B1 and RAGE reduced A to B CoQ10 transport to 44% and 50% of control 
respectively (Figure 2a), indicating that they normally mediate transport toward the brain. In 
contrast, LRP-1/LDLR inhibition with RAP revealed a 168% increase in A to B transport (Figure 2a), 
suggesting that this system normally opposes transport toward the brain. P-glycoprotein inhibition 
had no effect on transport across these cells. Interestingly, none of the inhibitors affected B to A 
transport (Figure 2b), which we would have expected in the case of LRP-1 inhibition by RAP. None 
of the interventions affected the paracellular permeability of the bEnd.3 monolayer to FITC-40 (Figure 
2f), so changes in transport were not due to BBB leak or altered BBB integrity. 
The “net” CoQ10 transport toward the brain side (A to B) is estimated from the difference 
between A to B transport, and B to A transport (Figure 2c). In control conditions, there is no “net” 
transport toward the brain side in the A to B direction (95% confidence interval, not different to zero). 
The only intervention to give a “net” positive transport A to B was when LRP/LDLR is inhibited with 
RAP, and this suggests LRP-1/LDLR is a major impediment to delivering CoQ10 to the brain. 
By contrast, transport of the idebenone, which is an analogue of CoQ10, showed “net” transport 
toward the brain, since A to B transport exceeded B to A (Figure 2e). Compared to CoQ10, the 
permeability of idebenone (Papp) was 280× greater in the A to B direction and 150× greater in the B to 
A direction. This is consistent with idebenone being able to cross the BBB directly, rather than as part 
of a lipoprotein, because idebenone satisfies Lipinsky’s rules for permeability as a small molecule 
drug (338 g/mol) with fewer than 10 hydrogen bond acceptors and LogP less than 5 [42]. 
Taken together, these data suggest that regulation of CoQ10 transport is determined by events 
on the blood side of the BBB, with transport systems working in opposing directions to limit the entry 
of lipoproteins, and therefore, limiting the entry of CoQ10 (Figure 2d). 
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Figure 2. Effect of inhibitors on CoQ10 transport across bEnd.3 BBB model. CoQ10 (pre-incubated in 
serum) transport across bEnd.3 cells on Transwell filters assayed over 60 min. Inhibitors added 
apically and basally two hours before assay were BLT-1 (10 μM) for SR-B1, FPS-ZM1 (1 μM) for 
RAGE, receptor-associated protein (RAP) (0.5 μM) for LRP-1/LDLR and verapamil (0.1 mM) for p-
glycoprotein. Apparent permeability, Papp, shown for (a) Apical to Basal CoQ10 transport, (b) Basal to 
Apical CoQ10 transport. (c) The “net” transport of CoQ10 across bEnd.3 cells, calculated from the 
difference between A to B transport (blood-to-brain) and B to A transport (brain-to-blood). “Net” 
transport in control cells did not differ from zero (95% confidence interval). * Treatment with SR-B1 
or RAGE inhibitors (BLT-1 10 μM, FPS-ZM1 1 μM) resulted in “net” −ve transport, i.e., “net” transport 
directed toward the blood side (B to A). † Treatment with LRP-1/LDLR inhibitor RAP (0.5 μM), 
resulted in “net” +ve transport toward the brain side (A to B). The p-glycoprotein efflux transport 
inhibitor Verapamil (0.1 mM) had no significant effect. (d) Schematic summary of CoQ10 transport 
across the BBB. No “net” CoQ10 entry toward brain side. Uptake by RAGE and SR-B1, is opposed by 
LRP-1/LDLR mediated removal to blood, a major impediment to brain entry of CoQ10. (e) Transport 
of the CoQ10 analogue, Idebenone (10 μM). Apical to basal transport exceeded basal to apical, meaning 
there was “net” transport toward the brain. n = 4-5, Values are mean ± SEM * p < 0.05. (f) FITC-40 
Apical to Basal transport; n = 8 (control), n = 4–5 (interventions); values are mean ± SEM; * p < 0.05, ** 
p < 0.01; ANOVA single factor; post-hoc Bonferroni. 
3.5. Inhibition of CoQ10 Biosynthesis 
CoQ10 biosynthesis was inhibited by treating the BBB cells with 1 mM pABA for five days before 
assay. As shown in Figure 3a, pABA competitively inhibits polyprenyl-4-hydroxybenzoate 
transferase (Coq2p), a key enzyme in the latter stages of the CoQ10 biosynthetic pathway. 
Assessment of cellular CoQ10 content in response to pABA treatment showed significant 
depletion of CoQ10 relative to controls of 36% and 43% in PBECs and bEnd.3 cells respectively (Figure 
3b). These results confirm that pABA treatment induces a pronounced CoQ10 deficiency in the in vitro 
BBB, at a magnitude that is consistent with clinical presentation [36]. Despite CoQ10 depletion, there 
was no change in cell viability (Figure 3c), indicating that the cells can tolerate pABA up to a 
concentration of 1 mM for up to 5 days, consistent with previous studies [29,43]. 
CoQ10 deficiency was also associated with a significant decrease in MRC enzyme activity across 
all complexes. MRC complexes I and II-III experienced the greatest relative decline in activity (68% 
and 72% decrease respectively, Figure 3d), with complex IV exhibiting a lesser effect (80% of control, 
Figure 3d). There was no significant change to citrate synthase activity (Figure 3d). 
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Figure 3. Effect of pABA on cellular CoQ10 content, cell viability and mitochondrial respiratory chain 
(MRC) complexes. (a) Schematic showing pABA inhibition of CoQ10 synthesis. (b) PBEC and bEnd.3 
cellular CoQ10 content after treatment with 1 mM pABA for 5 days (n = 4). (c) bEND.3 cell viability 
after 5 days treatment with CoQ10 (10 μM), or pABA 0.5 mM or 1 mM (n = 6). (d) Effect of 1 mM pABA 
treatment for 5 days on bEND.3 MRC complex I, II, III, and IV activity and citrate synthase (n = 4). 
Values are mean ± SEM; * p < 0.05, ** p < 0.01, *** p < 0.001 compared to control. 
As shown in Figure 4, BBB tight junction integrity was severely compromised after 5 days pABA 
treatment. In PBECs, the transendothelial electrical resistance (TEER) fell from 856 ± 71 Ω.cm2 to 49 ± 
9 Ω.cm2 (Figure 4a). This was accompanied by the re-location of claudin-5 tight junction protein away 
from the cell membrane (Figure 4b). Membrane staining was more punctate, with peri-nuclear 
accumulation after pABA treatment, consistent with disrupted or degraded tight junctions. Both BBB 
cell models were leakier to the paracellular marker FITC-40 (Figure 4c), and also showed increased 
transport of CoQ10 (Figure 4d) and idebenone (Figure 4e) which is consistent with paracellular leak. 
A consequence of a disrupted BBB is neurological symptoms, but also, paradoxically, more CoQ10 
could enter the brain. This would be advantageous for patients with CoQ10 deficiency, until sufficient 
CoQ10 was restored to the brain endothelial cells for the BBB integrity to be restored, therefore limiting 
further CoQ10 transport to the brain. This is consistent with the refractory nature of CoQ10 treatment, 
which eventually ceases being clinically effective. 
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Figure 4. Effect of pABA on in vitro BBB characteristics. BBB tight junction integrity after 5 days with 
pABA (1 mM) treatment is compromised. (a) PBEC transendothelial electrical resistance (TEER) 
declines; n = 6. (b) Confocal microscopy staining for claudin-5 tight junction protein in PBEC cells on 
Transwells. Upper panel is control, lower panel after 5 days with pABA (1 mM), shows reduced 
membrane localization of claudin-5 (40× magnification) PBEC and bEnd.3 monolayers are more leaky 
to (c) FITC-40, (d) CoQ10 and (e) idebenone. Values are mean ± SEM; PBEC n = 6, bEnd.3 n = 5–10; * p 
< 0.05, ** p < 0.01, *** p < 0.001. 
3.6. CoQ10 Defecient BBB: Effect of SR-B1, LDLR, and RAGE Inhibitors 
Despite the increased paracellular leak after pABA treatment, inhibitors of lipoprotein transport 
were able to modulate some aspects of CoQ10 transport, indicating that the BBB cells were still 
attempting to maintain homeostasis. The major difference was that SR-B1 inhibitor BLT-1, had no 
effect (Figure 5a), indicating that this system was inactive or ineffective after pABA treatment. 
However, the RAGE inhibitor FPS-ZM1 reduced Apical to Basal transport to 45% of control, 
suggesting that RAGE was still able to transport CoQ10 toward the brain side. The opposing LRP-
1/LDLR system also appeared active, with inhibition by RAP revealing an increased Apical to Basal 
transport of 164% of control (Figure 5a). As with control cells, neither Basal to Apical transport (Figure 
5b) nor paracellular leak measured by FITC-40 transport (Figure 5f) were affected by the inhibitors. 
Consistent with increased paracellular leak after pABA treatment, the “net” CoQ10 transport was 
different to control cell “net” zero (Figure 5c), and now showed a “net” positive transport toward the 
brain side (“net” +ve control Apical to Basal, Figure 5c). This was dependent, in part, on the action of 
RAGE, since inhibiting RAGE prevented “net” transport to the brain (net −ve). Inhibiting LRP/LDLR 
further enhanced transport to the brain side. Transport of idebenone was also increased, consistent 
with increased paracellular leak, with transport toward the brain side (A to B) greater than efflux to 
blood (B to A) (Figure 5e). 
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Figure 5. pABA treated bEnd.3 cells: Effect of transport inhibitors on CoQ10 transport. CoQ10 (pre-
incubated in serum) transport across pABA treated (1 mM; 5 days) bEnd.3 cells on Transwell filters 
assayed over 60 min. Inhibitors added apically and basally two hours before assay were BLT-1 (10 
μM) for SR-B1, FPS-ZM1 (1 μM) for RAGE, RAP (0.5 μM) for LRP-1/LDLR and verapamil (0.1 mM) 
for p-glycoprotein. Apparent permeability, Papp, shown for (a) Apical to Basal CoQ10 transport, (b) 
Basal to Apical CoQ10 transport. (c) The “net” transport of CoQ10 across bEnd.3 cells, calculated from 
the difference between A to B transport (blood to brain) and B to A transport (brain to blood). “Net” 
transport in pABA treated control cells was Apical to Basal, toward the brain side. * Treatment with 
RAGE inhibitor, FPS-ZM1 (1 μM), abolished “net” A to B transport. † Treatment with LRP-1/LDLR 
inhibitor RAP (0.5 μM), enhanced “net” +ve transport toward the brain side (A to B). The SR-B1 and 
p-glycoprotein inhibitors BLT-1 (10 μM) and Verapamil (0.1 mM), had no significant effect on “net” 
transport. (d) Schematic summary of CoQ10 transport across a CoQ10 deficient BBB. “Net” transport 
shifts toward to the brain side. Uptake via RAGE but SR-B1 is absent. Leaky tight junctions facilitate 
extra transfer across the BBB. Efflux via LRP-1 is retained. (e) Transport of the CoQ10 analogue, 
idebenone. Apical to Basal transport exceeded Basal to Apical, meaning there was “net” transport 
toward the brain. n = 6; values are mean ± SEM * p < 0.05. (f) FITC-40 Apical to Basal transport; n = 4–
7; values are mean ± SEM; * p < 0.05, ** p < 0.01; ANOVA single factor; post-hoc Bonferroni. 
3.7. Effect of Antioxidants on CoQ10 BBB Transport 
Alongside CoQ10, vitamin E (α-tocopherol) is a key component of the mito-cocktail, a therapeutic 
mixture of potent antioxidants and cofactors administered for the treatment of mitochondrial 
disorders [44,45]. Both α-tocopherol and CoQ10 are associated with circulatory lipoprotein, and share 
proposed uptake mechanisms mediated by SR-B1 [46], so further experiments were designed to 
measure CoQ10 transport in the presence of α-tocopherol. As a control, this was compared to the effect 
of the water-soluble synthetic analogue of α-tocopherol, Trolox, which does not interact with 
lipoproteins but provides antioxidant activity. 
Both antioxidants—α-tocopherol (Figure 6a) and Trolox (Figure 6b)—increased Basal to Apical 
transport of CoQ10 in control conditions, i.e., toward the blood side, although they both also increased 
Apical to Basal transport, i.e., toward brain side, slightly. However, with pABA treatment, CoQ10 
transport toward the blood-side, dominated flux (Figure 6c,d). If this translates to clinical CoQ10 
deficiency, then α-tocopherol co-administration with CoQ10 supplements would tend to reduce CoQ10 
delivery toward the brain, the opposite of the desired effect. 
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Figure 6. Antioxidants increase CoQ10 movement toward the blood side in bEnd.3 cells. Transport of 
CoQ10 across bEnd.3 monolayers on Transwell filters. CoQ10 (10 μM) was co-administered with either 
(a) vitamin E (50 μM) or (b) Trolox (50 μM) in control cells. Transport of CoQ10 in the direction B to A 
(toward blood side) was enhanced. In pABA treated cells to deplete CoQ10, the effect persisted and 
both (c) vitamin E and (d) Trolox enhanced B to A transport. Values are mean ± SEM; n = 4–6; * p < 
0.05, ** p < 0.01. 
4. Discussion 
The delivery of CoQ10 to the brain is a crucial requirement for the clinical treatment of the CNS 
sequelae of CoQ10 deficiency. However, how CoQ10 might enter the brain has not been clearly defined, 
which makes it difficult to target treatments effectively. Animal studies indicated a certain degree of 
CoQ10 transport across the BBB. Supplementing Sprague–Dawley rat diets with 200 mg/kg CoQ10 for 
2 months resulted in a 30% increase in cerebral cortex CoQ10 and CoQ9 (predominant ubiquinone in 
rat) [47]. Similarly, supplementation with high-dose (1000–5000 mg/kg) CoQ10 in a mouse model of 
Huntington`s disease significantly increased in brain levels of CoQ10 and CoQ9 [48]. However, it is 
uncertain from these studies whether this degree of cerebral uptake would be sufficient to replenish 
CoQ10 cellular levels in a CoQ10 deficient state. However, in patients with CoQ10 deficiency and CNS 
symptoms, there is limited clinical benefit of CoQ10 supplementation [5,8]. 
In this study, using an in vitro BBB model, we identify a key role for lipoproteins in CoQ10 
transport, and illustrate that modulators of lipoprotein function determine the bi-directional 
transport of CoQ10. In the absence of serum, CoQ10 transport was less than that of the non-transported 
marker FITC-dextran, but pre-incubation of CoQ10 with serum before the transport assay, increased 
transport 4-fold in the primary porcine BBB model. Assessment of CoQ10 distribution in serum 
lipoprotein fractions was broadly similar to that of human plasma [10,49], with most CoQ10 in the 
LDL fraction, followed by HDL and vLDL. Supplementation with 10 μM CoQ10 increased the 
absolute CoQ10 content in all lipoprotein fractions, but proportionately more for vLDL (29%), so taken 
together, the increased transport across the BBB model could have been mediated by a combination 
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of lipoproteins. Interestingly, transport in the Apical-to-Basal direction (A to B, blood-to-brain side) 
was matched by transport in the opposite Basal-to-Apical direction, resulting in no “net” 
accumulation of CoQ10 on the brain side because of opposing transport systems. This is consistent 
with the transport of lipoproteins across the BBB, which is thought to be limited because the adult 
brain synthesises sufficient cholesterol de novo [50], such that there is “net” efflux of cholesterol from 
the brain into blood. 
Transport systems for lipoproteins that have been identified at the BBB include Class B 
scavenger receptor B1 (SR-B1), and Low-Density Lipoprotein Receptor family including LDLR and 
LDL receptor-related protein (LRP-1) [51–53]. These transporters recognise lipoproteins via their 
apolipoprotein (Apo) component, however, LDLR and SR-B1 recognise diverse Apo including B-100 
and E for LDLR [54]; and A-I, E, and C for SR-B1 [55]. Similarly, lipoproteins may contain more than 
one type of Apo. For example, LDL and vLDL are rich in B-100 (LDLR ligand), and HDL is rich in 
Apo-A1 (SR-B1 ligand), but vLDL may also contain Apo C (SR-B1 ligand) [56], and all lipoproteins 
may contain Apo E (LDLR and SR-B1 ligand) [56,57]. This cross-reactivity makes attributing one type 
of lipoprotein to one type of transporter problematic, so for this study, we determined whether 
pharmacological inhibition of SR-B1 and the LDLR family of transporters could affect lipoprotein-
CoQ10 transport overall. We also screened for two further potential CoQ10 transporters systems, the 
receptor for advanced glycation end products (RAGE) which is a brain-directed uptake transporter, 
and the ATP-binding cassette efflux transporter P-glycoprotein (ABCB1) which prevents entry of a 
range of lipid-soluble compounds to the brain. 
Inhibitors of both SR-B1 and RAGE significantly reduced CoQ10 transport from A to B (blood to 
brain) by half, implicating them as important mediators of CoQ10 uptake to the brain. At the BBB, SR-
B1 mediates transcytosis of HDL across monolayers [58] from Apical to Basal sides, and is inhibited 
by excess HDL (Km of close to 5 μg/mL) indicative of a receptor-mediated event. In peripheral 
endothelial cells, SR-B1 also mediates transcytosis of LDL [59,60] in aorta ex vivo samples and 
coronary artery endothelial cells in culture. LDL transported across coronary endothelial cells was 
increased after overexpression of SR-B1 and reduced with competitive excess of LDL or HDL, which 
indicates a shared LDL/HDL receptor-mediated event for transport [59]. Interestingly, transcytosis in 
this model did not involve LDLR [59]. It was surprising that the effect of RAGE inhibition was similar 
to SR-B1 inhibition. RAGE is not documented to interact with lipoproteins, but is a pattern 
recognition receptor interacting with a broad range of negatively charged molecules [61], consistent 
with the anionic lipid and Apo components of lipoprotein [62], and is known to oppose LRP-1 
mediated amyloid-β efflux at the BBB [17,63–67]. In the brain, the inhibitor FPS-ZM1 binds 
exclusively to RAGE with multiple down-stream effects [68], including inhibition of amyloid-β 
uptake, and suppression of neuroinflammation. RAGE is capable of initiating endocytosis and uptake 
of plasma membrane-associated molecules such as HMGB1 and S100β via caveolin [69] and lipid-raft 
dependent pathways [70,71]. However, studies of RAGE-mediated lipoprotein transport have not 
been carried out, to our knowledge. 
In contrast to SR-B1 and RAGE mediated uptake of CoQ10, the LDLR transporters appear to 
oppose Apical-to-Basal uptake. Inhibition of LDLR transporters with RAP increased Apical-to-Basal 
uptake by 68% in the bEnd.3 BBB model. This was the only intervention to result in “net” transport 
toward the brain side in control cells and suggests that the LDLR family of transporters are a 
significant impediment to delivering CoQ10 to the brain. This was confirmed in our primary porcine 
cell model (Figure S1), where we applied RAP to the basal (brain side) of the cells, which inhibited 
the B-to-A efflux, so retaining CoQ10 on the brain side. Multiple LDLR family members may be 
inhibited by RAP including vLDL-R, apoE receptor 2, LDL-R, and LRP-1 [72]. LRP-1 is a possible 
candidate for this efflux transport because it is present on both faces of the BBB (brain and blood 
sides) but is responsible for the export of amyloid-β from the brain which is influenced by 
Apolipoproteins and inhibitable by RAP [53]. Similarly, vLDL appears to be responsible for ApoE4 
associated amyloid-β efflux from the brain, although this is slower than LRP-1 mediated efflux [73]. 
The LDLR, in contrast, is located on the luminal (blood facing) side of the BBB and mediates 
transcytosis from blood toward brain in bovine brain endothelial cells [51] and in LDLR-/-mice [74]. 
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Aside from LDLR, the other members of this family are less well studied specifically for lipoprotein 
transport at the BBB, and could be a fruitful avenue for future studies to improve CoQ10 retention by 
the brain. In addition, the use of LDLR inhibitors may also have potential therapeutic value as a 
means of increasing cellular CoQ10 levels in other patient groups which have been associated with a 
deficiency in the level of this isoprenoid, such as those with cardiovascular disease [75]. However, 
further studies will be required before this can be confirmed or refuted. 
The final inhibitor used was for the ABC efflux transporter, P-glycoprotein (P-gp), however, no 
significant effect was seen on CoQ10 transport across the BBB. P-glycoprotein has been implicated in 
inhibiting CoQ10 uptake in the Caco-2 intestinal epithelial-barrier model [18,76], such that inhibition 
of P-gp improves the permeability of CoQ10 across the intestinal barrier. However, closer inspection 
of the experimental procedures indicates the use of exogenous CoQ10 in its pure form as opposed to 
being associated with lipoprotein, or in a digestive micelle, meaning the transport mechanisms 
described do not reflect the true in vivo environment. Furthermore, the Caco-2 intestinal barrier-
model is a poor surrogate for BBB characteristics. Nevertheless, it was important to explore P-gp as 
a possible mode of CoQ10 efflux at the barrier, using a more reliable model of the BBB. 
To summarise the transport assays under control conditions, the findings from this study 
indicate that there is a “net” efflux of exogenous CoQ10 from the brain to the blood in the bEnd.3 BBB 
model. This is the first time a receptor-mediated efflux mechanism has been implicated for CoQ10 at 
the BBB and it is in agreement with the clinical ineffectiveness of CoQ10 therapy for the treatment of 
neurological disorders [77]. 
The development of a CoQ10 deficient BBB model gives further insight into CoQ10 transport to 
the brain, and this is the first time such a model has been developed. The use of para-aminobenzoic 
acid (pABA) as a pharmacological reagent to induce CoQ10 deficiency was first described in 1975 [28], 
and has since been utilised in studies of human myeloid leukemia HL-60 [43] and human 
neuroblastoma SH-SY5Y [29] cells. Compared with alternative techniques for inducing CoQ10 
deficiency, for example, gene silencing [78–80], the use of pABA, or other hydroxybenzoic acid 
derivates [81–83], is extremely cheap, very simple and highly reproducible. Building on previous 
findings from Duberley et al. [29], the primary porcine PBEC and murine bEnd.3 BBB cell models 
exhibited the depletion of CoQ10 to 36% and 57% of control respectively after 5 days treatment with 
pABA (1 mmol/L). This was concomitant with a depletion of MRC enzyme activity, in particular the 
CoQ10 dependent complexes II-III (28% of control) and complex I (32% of control). However, the 
treatment did not correspond to a cytotoxic effect, and is consistent with previous studies [29,43]. 
Interestingly, and in contrast to the work of Duberley et al. [29], the activity of MRC complex IV was 
the least affected (80% of control), suggesting there may be a cell- or tissue-specific variation in the 
susceptibility of the MRC enzymes to a CoQ10 deficiency. Overall, however, the deficiency profile is 
similar to that of fibroblasts from patients with a primary CoQ10 deficiency, indicating that pABA-
treatment is an appropriate surrogate for pathophysiological investigations [9,36,84]. 
Under pathophysiological CoQ10 deficient conditions, the BBB appeared severely disrupted. 
Permeability of PBEC and bEnd.3 BBB models increased to both FITC-dextran and CoQ10, and this 
was accompanied by reduced tight junction integrity, measured by a drop in transendothelial 
electrical resistance, and the re-location of tight junction protein claudin-5 away from the cell 
membrane which showed punctate staining. A study by Doll and colleagues [85] showed similar 
effects in a bEnd.3 BBB model using mitochondrial inhibitors rotenone, FCCP and oligomycin. They 
found the permeability to FITC-dextran was doubled, and staining for the tight junction protein ZO-
1 became punctate indicating disrupted cell–cell junctions. 
Along with the increase in permeability of the pathophysiological BBB model, the “net” direction 
of CoQ10 transport was reversed compared to control. Overall, CoQ10 transport now favoured the 
blood-to-brain direction. Among the transporters studied, SR-B1 appeared non-functional, RAGE-
inhibitable uptake increased from 50% to 55% of control while LDLR-inhibitable efflux reduced 
slightly from 68% to 63% of control, each contributing to “net” uptake of CoQ10 toward the brain. The 
overall implication is that under CoQ10 deficient conditions, with a disrupted BBB, transport of CoQ10 
toward the brain is possible. This raises the possibility that restoration of normal BBB cellular CoQ10 
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levels may also restore BBB integrity, but that would also prevent further access of CoQ10 to the brain. 
This intriguing possibility may be a reason why treating CNS symptoms of CoQ10 deficiency is 
refractory in nature, becoming less effective over time. 
In the final assays, we tested whether the addition of anti-oxidants could influence BBB transport 
of CoQ10, to mimic the “mito-cocktail” that is used clinically. The commonly used anti-oxidant, RRR-
α-tocopherol had no effect on Apical to Basal uptake of CoQ10 (from blood to brain sides). However, 
there was a significant effect on efflux, which increased in both the control and pathophysiological 
BBB model, leading to a “net” brain-to-blood transport. This effect was surprising, and the opposite 
of the effect desired for improving treatment. 
Since CoQ10 shares similar physicochemical properties to RRR-α-tocopherol and appears to 
follow analogous uptake mechanisms in vivo, including lipoprotein sequestration, we repeated the 
assay using a hydrophilic analog of RRR-α-tocopherol, Trolox, which should not interact with CoQ10 
at the level of the lipoprotein. The result however was the same, with increased efflux, resulting in a 
“net” loss of CoQ10 from the brain side. 
Of the transport systems for CoQ10 identified in this study, RAGE and LRP-1 function are shown 
to be sensitive to oxidative stress in a variety of tissue types. In general, RAGE and LRP-1 activity, or 
expression, increase in the presence of anti-oxidants, or in the absence of oxidative stress [86–88], and 
since these transporters are working in opposite directions across the BBB, the “net” result will be 
dependent upon which transporter is ultimately dominant. However, since the time-course of these 
experiments was relatively short (1 h), an alternative suggestion is that the reduced environment, 
with excess anti-oxidants, can affect lipoprotein binding to transporters, or their release after 
transcytosis. Indeed “reductive stress” has been implicated as a cause of BBB dysfunction and, 
therefore, merits further investigation given the important consequences for the treatment of CoQ10 
deficiency [89]. 
5. Conclusions 
This study demonstrated, for the first time, a dynamic interplay of multiple transport receptors, 
with varying degrees of influence, for the uptake and efflux of CoQ10 across the BBB. While there is 
substantial evidence for the involvement of RAGE, LRP-1 and SR-B1 in the transport of CoQ10 across 
the BBB, this is not predicted to be a comprehensive representation of all the receptors involved in its 
transport. The results show that the mechanisms governing uptake/efflux are complex and it is likely 
that there are many interactions occurring simultaneously; nevertheless, this study narrows down 
and isolates some key instigators, and also provides a solid foundation for further investigations. 
From a clinical perspective, these findings expand our biochemical knowledge of CoQ10, and 
imply that the uptake of exogenous CoQ10 into the brain could be improved by the administration of 
an LRP-1 inhibitor, or by implementing interventions that stimulate a luminal overexpression of 
RAGE and SR-B1. 
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